247 related articles for article (PubMed ID: 26093657)
21.
Lurje I; Werner W; Mohr R; Roderburg C; Tacke F; Hammerich L
Front Immunol; 2021; 12():650486. PubMed ID: 34025657
[TBL] [Abstract][Full Text] [Related]
22. Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma.
Ikeda M; Okusaka T; Ohno I; Mitsunaga S; Kondo S; Ueno H; Morizane C; Gemmoto K; Suna H; Ushida Y; Furuse J
Immunotherapy; 2021 Apr; 13(5):371-385. PubMed ID: 33525928
[No Abstract] [Full Text] [Related]
23. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.
He Y; Hong Y; Mizejewski GJ
Immunotherapy; 2014; 6(6):725-36. PubMed ID: 25041030
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.
Sun JC; Pan K; Chen MS; Wang QJ; Wang H; Ma HQ; Li YQ; Liang XT; Li JJ; Zhao JJ; Chen YB; Pang XH; Liu WL; Cao Y; Guan XY; Lian QZ; Xia JC
Cancer Biol Ther; 2010 Aug; 10(4):368-75. PubMed ID: 20581468
[TBL] [Abstract][Full Text] [Related]
25. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.
Bertino G; Demma S; Ardiri A; Proiti M; Mangia A; Gruttadauria S; Toro A; Di Carlo I; Malaguarnera G; Bertino N; Malaguarnera M; Malaguarnera M
Biomed Res Int; 2015; 2015():731469. PubMed ID: 25893197
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
Tian M; Shi Y; Liu W; Fan J
Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
[TBL] [Abstract][Full Text] [Related]
27. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
Seifi-Alan M; Shamsi R; Ghafouri-Fard S
Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
[TBL] [Abstract][Full Text] [Related]
28. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
29. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma.
Dong HL; Li ZS; Ye J; Qu P; Huang YY; Wu W; Lu SY; Chen GS; Sui YF
Cancer Biol Ther; 2004 Sep; 3(9):891-8. PubMed ID: 15326372
[TBL] [Abstract][Full Text] [Related]
30. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
[TBL] [Abstract][Full Text] [Related]
31. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses.
Zuo B; Zhang Y; Zhao K; Wu L; Qi H; Yang R; Gao X; Geng M; Wu Y; Jing R; Zhou Q; Seow Y; Yin H
J Hematol Oncol; 2022 Apr; 15(1):46. PubMed ID: 35488312
[TBL] [Abstract][Full Text] [Related]
32. HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
Kikodze N; Mazmishvili K; Iobadze M; Rekhviashvili Kh; Nanava N; Pantsulaia I; Mizandari M; Janikashvili N; Chikovani T
Georgian Med News; 2015 Sep; (246):78-84. PubMed ID: 26355320
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
34. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma.
Chen Y; Yang D; Li S; Gao Y; Jiang R; Deng L; Frankel FR; Sun B
Oncogene; 2012 Apr; 31(17):2140-52. PubMed ID: 21927025
[TBL] [Abstract][Full Text] [Related]
35. Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC).
Berretta M; Cobellis G; Franco R; Panarese I; Rinaldi B; Nasti G; Di Francia R; Rinaldi L
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10139-10150. PubMed ID: 31799686
[TBL] [Abstract][Full Text] [Related]
36. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
37. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Schmidt N; Neumann-Haefelin C; Thimme R
Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
Liu X; Qin S
Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding JJ; El Dika I; Abou-Alfa GK
Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
[TBL] [Abstract][Full Text] [Related]
40. Specific CD8(+ )T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination.
Zhang HG; Chen HS; Peng JR; Shang XY; Zhang J; Xing Q; Pang XW; Qin LL; Fei R; Mei MH; Leng XS; Chen WF
Cancer Immunol Immunother; 2007 Dec; 56(12):1945-54. PubMed ID: 17522859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
